

1 Chemical Isotope Labeling Exposome (CIL-EXPOSOME): One High- 2 Throughput Platform for Human Urinary Global Exposome 3 Characterization

4 Shenglan Jia,^{†,‡,§} Tengfei Xu,^{†,§} Tao Huan,^{||} Maria Chong,[†] Min Liu,^{†,‡} Wenjuan Fang,[‡]
5 and Mingliang Fang^{*,†,§,⊥}

6 [†]School of Civil and Environmental Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798

7 [‡]Residues and Resource Reclamation Centre, Nanyang Environment and Water Research Institute, Nanyang Technological
8 University, 1 Cleantech Loop, CleanTech One, Singapore 637141


9 [§]Advanced Environmental Biotechnology Centre, Nanyang Environment & Water Research Institute, Nanyang Technological
10 University, Singapore 637141

11 ^{||}Department of Chemistry, University of British Columbia, Vancouver Campus, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1

12 [⊥]Analytics Cluster, Nanyang Environment and Water Research Institute, Nanyang Technological University, 1 Cleantech Loop,
13 CleanTech One, Singapore 637141

14 **S** Supporting Information

15 **ABSTRACT:** Human exposure to hundreds of chemicals, a
16 primary component of the exposome, has been associated
17 with many diseases. Urinary biomarkers of these chemicals are
18 commonly monitored to quantify their exposure. However,
19 because of low concentrations and the great variability in
20 physicochemical properties of exposure biomarkers, exposome
21 research has been limited by low-throughput and costly
22 methods. Here, we developed a sensitive and high-throughput
23 exposome analytical platform (CIL-EXPOSOME) by isotopically
24 labeling urinary biomarkers with common functional
25 groups (hydroxyl/carboxyl/primary amine). After a simple
26 cleanup, we used mass spectrometry to perform a screening
27 for both targeted and untargeted biomarkers, which was further processed by an automatic computational pipeline method for
28 qualification and quantification. This platform has effectively introduced an isotope tag for the absolute quantification of
29 biomarkers and has improved sensitivity of 2–1184 fold compared to existing methods. For putative identification, we built a
30 database of 818 urinary biomarkers with MS/MS fragmentation information from either standards or in silico predictions. Using
31 this platform, we have found 671 urinary exposure biomarker candidates from a 2 mL pooled urine sample. The exposome data
32 acquisition and analysis time has also been greatly shortened. The results showed that CIL-EXPOSOME is a useful tool for
33 global exposome analysis of complex samples.



34 ■ INTRODUCTION

35 The concept of the “exposome”, which is a measure of the
36 effects of life-long environmental exposure on health, has been
37 a hot topic since its introduction in 2005.¹ Recent initiatives in
38 environmental exposome research have attempted to map the
39 complex relationships between biomarkers and disease
40 risks.^{2–4} Therefore, measurable and characteristic changes of
41 all biomarkers taken together form the key foundation of
42 exposome research.⁵ Exposure biomarkers possess enormous
43 structural diversity and have a broad concentration range
44 (from 10⁻⁷ μM to 1 mM for environmental pollutants).^{6,7}
45 Meanwhile, we are constantly exposed to an array of ever-
46 increasing chemicals, both endogenous and exogenous, from
47 our diet, the environment, and our behavior.⁸ As such, profiling

48 a large number of exposure biomarkers requires powerful
49 analytical techniques with broad coverage and high sensitivity.

50 Current exposure analytical methods include both tradi-
51 tional targeted measurement and untargeted discovery of
52 chemicals with biological importance (mainly endogenous
53 metabolites).^{9–11} For targeted approaches, high sensitivity,
54 wide dynamic range, and good reproducibility are achieved
55 with complex cleanup steps and expensive chemical isotope-
56 labeled (CIL) analogues.¹² Moreover, the targeted method can
57 measure only several biomarkers at one time and requires large

Received: January 14, 2019

Revised: March 27, 2019

Accepted: April 3, 2019

Published: April 3, 2019






Figure 1. Workflow for the determination and quantitation of hydroxyl/primary amine and carboxyl exposure biomarkers in human urine by the CIL-EXPOSOME platform. Following derivatization and sample processing, the LC-qTOF raw data were imported into the IsoMS and suspect exposure biomarkers were searched against the compounds in the CIL-EXPOSOME database under different mass accuracy tolerances. The resulting information (name, mass tolerance, accurate mass, and m/z light) was exported. The exposure biomarker candidates were further confirmed with MS/MS (i.e., MS²) fragmentation.

58 volumes of sample. Untargeted approaches have primarily
 59 evolved from global metabolomics methods, by combining
 60 advanced analytical and computational tools.¹³ Untargeted
 61 metabolomics retain a broad coverage of analytes by sacrificing
 62 sensitivity, making the approach inefficient at measuring low-
 63 concentration environmental chemicals.^{5,14} Therefore, there is
 64 a great demand for a sensitive and high-throughput platform,
 65 capable of capturing both endogenous and low-level exogenous
 66 exposure biomarkers.

67 Among all biological samples, urine samples have a great
 68 potential to be used in long-term exposome characterization
 69 because of their noninvasive nature and easy collection.¹⁵ Most
 70 environmental chemical exposure biomarkers are excreted and
 71 can be found in the urine following oxidation, reduction, or
 72 hydrolysis and further phase II conjugations.¹⁶ However, high
 73 concentrations of salts and the diversity of chemical
 74 compounds present make the analysis of urinary exposure
 75 biomarkers across a wide range of concentrations challenging.

76 To address this analytical challenge and establish a sensitive,
 77 high-throughput exposome platform, we applied a chemical-
 78 derivatization method for exposome profiling in urinary
 79 samples. Chemical isotope labeling combined with liquid
 80 chromatography–mass spectrometry (CIL-LC-MS) analysis
 81 was used to enhance the detection of both endogenous and
 82 exogenous compounds, simplifying both data acquisition and
 83 processing during exposome analysis. CIL-LC-MS could
 84 significantly improve chemical detection and quantification of
 85 endogenous metabolites, with sensitivity increases of 10–1000-
 86 fold observed in previous studies.^{17–19} Furthermore, isotope
 87 forms of the derivatization reagents can be used as an
 88 economical internal standard for absolute quantification.^{20,21}

89 After the metabolites were categorized into several subgroups
 90 based on their functional moieties (i.e., carboxyl, carbonyl,
 91 amine, etc.), different labeling chemistries can be used to
 92 profile different submetabolomes in order to provide better

coverage of the entire compound range of interest.^{22,23} For
 93 most exogenous biomarkers in the urinary exposome, either
 94 the parent compound or metabolites commonly contain
 95 hydroxyl or carboxylic acid functional groups to enhance
 96 their aqueous solubility, making the CIL method promising for
 97 this application.²⁴

98 Here, we present a urinary exposome profiling workflow that
 99 employs CIL and automatic data processing to examine
 100 hydroxyl/primary amine and carboxyl biomarkers originating
 101 from both endogenous and exogenous chemicals. This
 102 approach provides a solution to several challenges currently
 103 limiting exposure biomarker profiling. First, CIL methods were
 104 used to increase sensitivity and greatly improve the coverage of
 105 exposure biomarkers. Second, an automatic data processing
 106 approach was built up to confirm potential exposure
 107 biomarkers, enabling fast screening and compound identifi-
 108 cation. Finally, the method's performance was validated in a
 109 pooled human urine sample, demonstrating that the CIL-
 110 EXPOSOME workflow is a promising tool for future global
 111 exposome analysis.
 112

113 MATERIALS AND METHODS

114 **Chemicals and Stock Preparation.** All chemicals and
 115 reagents were purchased from Sigma-Aldrich Singapore
 116 (Singapore) except those otherwise noted. The labeling
 117 reagent, *p*-dimethylaminophenacyl bromide (DmPA), was
 118 purchased from Apollo Scientific Ltd. (Stockport, U.K.). The
 119 isotope reagents, ¹³C₂-dansyl chloride (DNS) and ¹³C₂-*p*-
 120 dimethylaminophenacyl bromide, were purchased from TMIC
 121 (Edmonton, Canada). ¹³C₁₂-BPA, ¹³C₆-monobenzyl phthalate,
 122 and ¹³C₄-methyl paraben were purchased from Cambridge
 123 Isotope Laboratories (Andover, MA, United States). HPLC
 124 grade water, ethyl acetate, and acetonitrile (ACN) were
 125 purchased from Thermo Fisher Scientific (Singapore).

126 **Standard Solution Preparation.** Twenty-two hydroxyl- or
127 carboxyl- containing standards were chosen to optimize the
128 analytical method. Additional information is provided in Table
129 S1. Each compound dissolved in ACN at a concentration of 10
130 mg/mL. Seven-level mixed standard working solutions (10, 1,
131 0.1, 0.01, 0.001, 0.0001, 0.00001 $\mu\text{g/mL}$), also serving as
132 calibration standards, were prepared with ACN through serial
133 dilution of stock solutions for method validation. In addition,
134 three-level quality control (QC) working solutions were
135 prepared in a similar manner to provide low (0.0001 $\mu\text{g}/$
136 mL), medium (0.01 $\mu\text{g/mL}$), and high (1 $\mu\text{g/mL}$) level
137 controls. All stock and working solutions were stocked at -40
138 $^{\circ}\text{C}$ and diluted with ACN to the desired level before use.

139 **Urine Sample Collection and Preparation.** A pooled
140 human urine sample was prepared by mixing first morning
141 voids of 35 volunteers (healthy, ages 22–37) which were
142 immediately frozen at -20 $^{\circ}\text{C}$ after sampling. Informed written
143 consent was obtained from all participants. Institutional
144 Review Board approval for human specimen analysis were
145 obtained from Singapore (IRB-2017-02-023). The pooled
146 urine sample was buffered to pH 5.5 and treated with an
147 enzyme mixture (β -glucuronidase/sulfatase) for 12 h at 37 $^{\circ}\text{C}$.
148 After centrifugation (10 min, 16000g, 4 $^{\circ}\text{C}$), the urine was
149 processed with labeling reagents for method development.
150 Spiking experiments were performed by adding a mixed
151 working solution of the selected compounds or surrogate
152 standards to the pooled samples before sample preparation.

153 **CIL-EXPOSOME Procedure. Work Flow.** In this study,
154 two CIL methods were used to profile hydroxyl/primary
155 amine/carboxyl endogenous and exogenous biomarkers. Figure
156 1 illustrates the overall workflow of the method and data
157 processing design with the following steps: (1) dansylation or
158 *p*-dimethylaminophenacyl bromide (DmPA) labeling of the
159 deconjugated urine sample; (2) equal amounts of $^{12}\text{C-}/^{13}\text{C-}$
160 dansylation/DmPA were mixed with labeled samples; (3)
161 liquid–liquid extraction was performed to enrich the labeled
162 biomarkers from above complex mixtures; (4) raw LC-qTOF
163 analysis data were imported into IsoMS (Test S1) to get
164 $^{12}\text{C-}/^{13}\text{C-}$ peak pairs; (5) the exported paired suspect
165 biomarkers were mass matched to the database under mass
166 accuracy tolerance (e.g., < 20 ppm); (6) the resulting
167 information (biomarker candidate name, mass tolerance, and
168 m/z) were exported; and (7) the exported biomarker
169 candidates were processed and putatively identified with
170 standard or in silico predicted MS/MS fragmentation pattern.

171 **Reaction Method Optimization.** To optimize the deriva-
172 tization conditions, three-level quality control (QC) mixed
173 standard solutions reflecting human relevant levels were
174 utilized. The mixtures were allowed to react under different
175 concentrations of derivatization reagent, preparation times of
176 derivatization reagent, ACN/H₂O percentages, reaction
177 temperatures, and incubation times individually. A detailed
178 description of the labeling reaction can be found in Text S2.

179 **LC-qTOF Profiling and MS/MS Fragmentation Acquis-
180 ition.** Standard and urine analyses were performed using a
181 high-performance liquid chromatography (HPLC) system
182 (1200 series, Agilent Technologies) coupled to an Agilent
183 6550 quadrupole time-of-flight (qTOF) mass spectrometer
184 (Agilent, Singapore). Samples were injected for reversed-phase
185 analysis in electrospray ionization (ESI) positive and negative
186 modes, as detailed in Text S3. The instrument was set to
187 acquire over a mass-to-charge ratio (m/z) range from 50 to
188 1700 with the MS acquisition rate of 2 Hz. For the acquisition

of MS/MS spectra of selected precursors, the default isolation
width was set to 1.3 Da with MS and MS/MS acquisition rates
of 4 Hz. The collision energy was set to 20–40 eV. Data were
processed by using the CIL-EXPOSOME data processing
approach as described in Results and Discussion.

**CIL-EXPOSOME Method Validation. Linearity and
Sensitivity.** Calibration was conducted based on the analysis
of derivatized 7-level labeled mix standard working solutions.
Calibration curves were established by using linear regression.
The LOD and LOQ were estimated as 3 and 10 times of the
standard deviation calculated from 6 replicates at the lowest
spiking level, respectively.

Precision and Accuracy. Three-level derivatization standard
quality control (DQC) working solutions were prepared to
provide low, medium, and high scenarios of human biomarker
concentration. Intra- and interday precision and accuracy were
assessed by using relative standard deviation (RSD) within a
day ($n = 6$) and on three consecutive days ($n = 9$),
respectively.

Stability and Cleanup Efficiency. Sample preparation
stability of all derivatives was evaluated by analysis of the
DQC solutions at 48 h (28 $^{\circ}\text{C}$) and -40 $^{\circ}\text{C}$ at 30-day
intervals. Pooled urine samples spiked with DQC solutions
were prepared to evaluate the cleanup efficiency, which was
defined as the response ratio of extracted concentrations from
a spiked sample to the same concentrations of DQC. Each
measurement was performed in triplicate.

Matrix Effect. In the absence of a biomarker-free urine
matrix, a pooled urine sample was processed as described in
Urine Sample Collection and Preparation and divided into two
parts (A and B). Part A was dried to prepare the urine matrix,
and an equal volume of DQC solutions were added to estimate
the influence of the matrix effect. Part B was analyzed directly
to determine the background concentration of each analyte.
The matrix factor of each compound was calculated by
difference between part A and DQC relative to the response of
DQC in pure solvent. To further distinguish the matrix effect
from derivatization efficiency, $^{13}\text{C}_6$ -monobenzyl phthalate and
 $^{13}\text{C}_4$ -methyl paraben were added before derivatization to
examine the derivatization efficiencies on the two types of
labeling. Labeled $^{13}\text{C}_{12}$ -BPA was dansylated and added before
injection as a recovery standard to assess the matrix effect.

**Statistical Analyses and Quality Assurance/Quality
Control (QA/QC).** One-way ANOVA and Tukey's posthoc
test were used to compare the response difference during
optimization. Procedure MiliQ-water blanks were prepared to
evaluate contamination arising from laboratory materials and
solvents. An ACN blank was injected after 6 samples, and a
calibration check standard was injected after every 12 samples.

RESULTS AND DISCUSSION

**CIL-EXPOSOME Chemical Derivatization Method
Development. Derivatization Reagent Selection.** One of
the important considerations in developing labeling chemistry
is how to tag the urinary biomarkers with differential isotopic
groups in a robust way. In this study, we evaluated the
functional groups of urinary biomarkers from a recent
published comprehensive database (Exposome Explorer).²⁵
Together, biomarkers with hydroxyl, primary amine, and
carboxylic functional groups consist of $>70\%$ of the total
database. Hydroxyl compounds and primary amines are
preferentially labeled with dansylation methods.^{18,26,27} The
derivatization of carboxylic acids can be conducted with a

variety of chemical reactions for analytical applications, and phenacyl bromide has been used to label the acids for improved HPLC and UV detection.²⁸ However, a new reagent, DmPA, was designed that allows for the introduction of a mass tag and concurrent improvement during LC-MS analysis.¹⁹ Here, we used dansyl chloride (DnsCl) and DmPA to label hydroxyl/primary amine and carboxyl urinary biomarkers, respectively.

Reaction Condition Optimization. Although the stable isotope labeling method has been previously optimized for the endogenous metabolites,^{29–31} the derivatization efficiency of high-concentration endogenous (μM to mM level) and low-concentration xenobiotic biomarkers (nM or pM level) may vary from each other. Furthermore, compared to endogenous metabolites, the chemical structure of xenobiotics and their biotransformation products are more diverse. To optimize the labeling conditions for urinary biomarkers, MiliQ water and urine spiked with three-level QC working solutions were labeled under different reaction conditions. Figure 2a,b shows

compounds, ACN/ H_2O (1:1, v/v) was selected as the reaction solvent for dansylation. The reaction temperature and time also had an effect on the labeling efficiency. We found that the optimal conditions were 40 min at 40 °C, which differs from the optimal conditions for endogenous metabolites.¹⁸ The optimal mole ratio of compound to DnsCl was 1:10⁵. The optimization results for urine were the same as those for the MiliQ water, except that the mole ratio of compound to DnsCl increased to 1:10⁶.

Under both MiliQ water and urine background, 80% ACN/ H_2O was selected as the reaction solvent for DmPA reaction, and the optimized reaction temperature and time were found to be 90 °C for 60 min (Figure S1a,b). The mole ratio of compound to DmPA was optimal at 1:10⁴ for MiliQ water and 1:10⁵ for urine.

Cleanup Method Optimization. A proper cleanup method is crucial to minimizing matrix effects. In the present study, we compared the recoveries of a few pretreatment methods: (1) extraction of the free biomarkers from MiliQ water followed by derivatization (LLE-Label); (2) biomarker derivatization in MiliQ water followed by extraction (Label-LLE, Label-SPE); (3) extraction of free biomarkers from urine followed by derivatization (urine LLE-Label); and (4) biomarker derivatization in urine followed by extraction (urine Label-LLE). As shown in Figure 2c, derivatized standards were more efficiently extracted by the liquid–liquid extraction (LLE) strategy than free standards in both MiliQ water and urine. This is probably because the derivatization step increases the hydrophobicity of hydroxyl, amines, and carboxylic acids in the urine sample. As a result, the chemicals are more likely to partition to the organic phase.¹⁷ Sample processing was also streamlined by combining DnsCl- and DmPA-derivatized samples prior to extraction. Finally, the optimized cleanup in this study was simplified with a single liquid–liquid solvent extraction, which was enabled by the use of the nonpolar derivatization reagent. Details are as follows: (1) Equal amounts ¹²C-/¹³C₂-DnsCl/DmPA labeled urine samples were combined to profile hydroxyl/primary amine and carboxyl biomarkers. (2) Saturated NaCl solution (v/v, 1:5) was added to the mixture then extracted with ethyl acetate twice (v/v, 1:3). (3) The extracted solutions were combined and dried, followed by reconstitution in ACN prior to LC-qTOF injection.

Method Performance Validation. Sensitivity and Separation Improvement. After derivatization, both the sensitivity and retention of all the tested compounds were greatly improved compared with their nonderivatized counterparts (Figure 2d,e). A similar finding was observed for the urine samples (Figure S2). The results showed that the detection sensitivities of these standard compounds generally increased by 2–1184 fold upon chemical labeling (Table S2). Before derivatization, only three of the free form hydroxyl compounds (bisphenol S, benzoescorcinol, and genistein) were detected at the concentration of 10 ppb. Chemical labeling not only will efficiently improve the detection sensitivities but also will lead to the discovery of more low-abundance biomarkers. The chromatographic separation also showed significant improvement after derivatization. Because of the diverse chemical structures and physicochemical properties among biomarkers, separation of these compounds in a complex urine sample is not readily accomplished with a single LC method. Derivatization can overcome this difficulty by introducing a hydrophobic functional group to the analytes. Following derivatization, sufficient separation can be accomplished by




Figure 2. Comparison of labeling efficiencies for 15 hydroxyl standards (a) spiked in MiliQ water and (b) spiked in urine under different labeling reaction conditions. From left to right: reaction time, reaction temperature, incubation solvent, DnsCl preparation time, and compound:DnsCl mole ratio. (c) Comparison of cleanup method optimization for standards under different cleanup procedures. All data in panels a–c are presented as the mean from three separate experiments ($n = 3$) of three levels of QC working solution (0.1, 10, and 1000 ppb). Extracted ion chromatograms of labeled standard mixture (d) after derivatization and (e) before derivatization (10 ppb each). The compounds are shown as follows: 1, methylparaben; 2, ethylparaben; 3, 4-bromophenol; 4, 1-naphthol; 5, benzylparaben; 6, 2-hydroxyfluorene; 7, butylparaben; 8, 9-phenanthrol; 9, bisphenol S; 10, benzoescorcinol; 11, 1-hydroxypyrene; 12, triclosan; 13, bisphenol A; 14, genistein; 15, 3,5-DHPPA.

the effects of reaction solvent, time, temperature, DnsCl/compound mole ratio, and DnsCl preparation time (from left to right) on the efficiency of standard dansylation. For the pure chemical optimization, results indicate that the effect of water in the incubation solvent on the labeling efficiency is compound-dependent. After the optimization of all the tested




Figure 3. Composition of CIL-EXPOSOME biomarker database: number of compounds ($n = 818$) by chemical classes.




Figure 4. Fragmentation pattern of chemically labeled products. (a) DNS-labeled hydroxyl compound; (b) $^{13}\text{C}_2$ -DNS-labeled hydroxyl compound; (c) DmPA-labeled carboxylic acid; (d) $^{13}\text{C}_2$ -DmPA-labeled carboxylic acid. Highlighted in blue and green are the theoretical and labeled m/z , respectively.

339 using simple reverse phase chromatography. By chromatographic optimization, the derivatization methods greatly 340 reduced the analysis time in the traditional targeted analysis, 341 especially for polar biomarkers that are not retained by regular 342 reverse-phase chromatography. 343

344 **Analytical Figures of Merit.** We estimated a series of 345 attributes of the proposed quantification method, such as 346 calibration range, linearity, sensitivity, precision, accuracy, 347 stability, extraction efficiency, and matrix effect. The linearities 348 of calibration curves for all analytes were excellent among the 349 validated concentration range of 100 ppt to 1 ppm, with 350 determination coefficients (R^2) greater than 0.99. Because of 351 the diversity of biomarker concentrations, we considered two

injection volumes (1 and 10 μL) to avoid response saturation. 352 As shown in Table S2, all analytes had an LOQ lower than 1 353 ppb. The analytical method was shown to be highly 354 reproducible, with all of the relative standard deviations 355 (RSDs) less than 20% for both intraday and interday variations 356 (Table S3). The stability of all derivatized standards had 357 coefficients of variation (CVs) that were $\leq 18\%$ and $\leq 16\%$ for 358 storage at 28 $^\circ\text{C}$ for 48 h or at -20 $^\circ\text{C}$ for 30 days, respectively 359 (Table S4). Extraction efficiencies of three-level DQC using 360 the above optimized cleanup method were approximately 73– 361 92% (Table S5). The interference of the matrix with the 362 analytes was within 40% (Table S5). 363




Figure 5. Chemical isotope-labeled urine sample analyzed by the CIL-EXPOSOME platform. Extracted ion chromatograms of (a) exposure biomarker examples from ~671 potential hydroxyl/primary amine and carboxylic acid metabolites from combined DNS/ $^{13}\text{C}_2$ -DNS and DmPA/ $^{13}\text{C}_2$ -DmPA-labeled urine sample. Fifteen exposure biomarkers have been confirmed with authentic standards, namely, 1, methylparaben; 2, 4-bromophenol; 3, naphthol; 4, BPS; 5, benzo(a)pyrene; 6, triclosan; 7, BPA; 8, genistein; 9, 3,5-DHPPA; 10, *trans,trans*-muconic acid; 11, 4-ethylphenol; 12, 2,4-di-*tert*-butylphenol; 13, 2-methylphenol; 14, 2-isopropoxyphenol; and 15, 4-propoxyphenol. An example of MS/MS from the newly identified (b) hydroxyl compound 4-ethylphenol and (c) carboxylic acid *trans,trans*-muconic acid. (d) Correlation of BPA abundance between LC-QQQ and the CIL-EXPOSOME platform ($R^2 = 0.98$, $p < 0.001$) from 9 urine samples. (e) Absolute quantification of 9 targeted compounds detected in the pooled mixture of urine samples ($n = 35$).

364 CIL-EXPOSOME Biomarker Database. To further facilitate
 365 the identification of urinary biomarkers, we established a
 366 urinary CIL-EXPOSOME biomarker database. Each entry in
 367 the exposure database included the chemical name, accurate

molecular weight, exposure source, chemical class, predicted
 368 exact m/z after being labeled, MS/MS fragmentation, and a
 369 detailed information link (HMDB, KEGG, or PUBCHEM).
 370 To create a broad exposome database, the CIL-EXPOSOME
 371

372 biomarker database was compiled from a few existing data
373 sources: Exposome-Explorer database,²⁵ Human Metabolome
374 Database (HMDB),³² the U.S. National Health and Nutrition
375 Examination Survey (NHANES),³³ and MyCompoundID
376 database.³⁴ The MS/MS fragmentation of urinary biomarkers
377 was either generated using authentic standards or predicted
378 using CFM-ID (see below). As a result, the CIL-EXPOSOME
379 biomarker database that was established (Table S6) included
380 818 reported hydroxyl/primary amine and carboxyl biomarkers
381 from food, drugs, endogenous metabolites, plasticizers, person-
382 al care products (PPCPs), polybrominated diphenyl ethers
383 (PBDEs), polycyclic aromatic hydrocarbons (PAHs), poly-
384 chlorinated biphenyls (PCBs), phthalates, pesticides, and flame
385 retardants (excluding PBDEs) (Figure 3).

386 **CIL-EXPOSOME MS/MS Fragmentation Pattern and**
387 **Database Development.** MS/MS fragmentation provides an
388 important criteria for compound identification. In the present
389 study, we created a MS/MS fragmentation library of ~100
390 xenobiotics and their biotransformation products by conduct-
391 ing dissociation at different collision energies (0, 10, 20, and 30
392 eV). Together with ~250 MS/MS spectra of endogenous
393 metabolites from mycompound ID,³⁵ we have generated a
394 MS/MS database composed of ~350 authentic standards. For
395 the rest of the compounds in the database, in silico MS/MS
396 information was predicted using a machine-learning method
397 (CFM-ID).³⁶ The database is available to the public via
398 Google Drive ([https://drive.google.com/drive/folders/
399 li1UNhfwMh_ry97TH6-FKGE_m_A-i-oleU?usp=sharing](https://drive.google.com/drive/folders/li1UNhfwMh_ry97TH6-FKGE_m_A-i-oleU?usp=sharing)).

400 We further investigated the MS/MS fragmentation behavior
401 of compounds labeled by two reagents (DnsCl and DmPA). As
402 shown in Figure 4, the expected precursor ions were m/z
403 378.1/380.1 for DNS/¹³C₂-DNS-labeled naphthol and m/z
404 418.1/420.1 for DmPA/¹³C₂-DmPA-labeled monobenzyl
405 phthalate. The DNS/¹³C₂-DNS-labeled hydroxyl compounds
406 generated two characteristic product ions, 171.1/173.1 and
407 235.0/237.0, by neutral loss from the precursor ion, $[M + H]^+$.
408 For naphthol, another characteristic product ion was formed,
409 $[M + H]^+$ 207.0, which is the parent ion of $[M + H]^+$ 171.1/
410 173.1 (Figure 4a,b). The DmPA/¹³C₂-DmPA-labeled carbox-
411 ylic acids typically lose the common derivatization group (m/z
412 149.0/151.0). The resulting product ion $[M + H]^+$ 270.1 for
413 monobenzyl phthalate was formed (Figure 4c,d). Overall, we
414 have observed m/z 171.1 and 235.0 as two typical fragments
415 for dansylation and m/z 149.0 as a typical fragment for the
416 DmPA label. The molecular MS fragment feature of the
417 targeted compounds can also be observed in other MS/MS
418 fragmentation patterns. The use of the selected paired peaks
419 after chemical labeling as the targeted precursor ions facilitates
420 subsequent MS/MS analysis. In addition, the characteristic
421 fragmentation of metabolites after chemical labeling make
422 identification feasible. This strategy can narrow down the
423 candidate compounds from fragmentation ions.

424 **CIL-EXPOSOME Automatic Profiling Workflow.** In
425 addition to working as an internal standard, ¹³C reagent-
426 labeled biomarkers can play a unique role in untargeted
427 profiling and identification. Here, the obtained full scan (MS)
428 raw data was processed by IsoMS to extract ¹²C/¹³C peak pairs
429 from mass spectra. The paired peaks with a defined mass
430 difference (2.0067 Da for one light/heavy labeled metabolites),
431 tolerance window (e.g., <20 ppm), and intensity ratios (0.80–
432 1.20) were extracted from the spectra. Information on detected
433 compounds, including accurate m/z , retention time (t), and

peak intensity, was generated for each exposure biomarker 434
candidate (Table S7). 435

We further designed a MATLAB program to automatically 436
search the exposure biomarker candidate peak pairs against the 437
CIL-EXPOSOME biomarker database; the detailed manual 438
can be found in Google Drive. On the basis of the IsoMS 439
preselected mass list, the prospective candidates of each 440
exposure biomarker were output with mass tolerance, name, 441
database ID, accurate mass, and labeled accurate mass (Figure 442
S3). Users can select different values to use for mass tolerance. 443
For the identification, targeted MS/MS fragmentation of the 444
potential biomarker was generated with a qTOF mass 445
spectrometer. qTOF parameters included width of 1.3 m/z 446
units and a collision energy of 20 V. The obtained MS/MS 447
fragmentation spectra were then further matched with 448
prospective candidates in the established MS/MS library. 449
Additionally, compounds were excluded that did not meet the 450
following specifications: (1) targeted MS/MS of the potential 451
biomarker included 171.1/173.1 or 149.0/151.0 in the native 452
and isotope-labeled compounds and/or (2) the MS/MS 453
fragment matched with the precursor compounds. 454

CIL-EXPOSOME Platform Application. With the estab- 455
lished method, we determined the chemical and exposure 456
biomarkers in the pooled urine sample. Using this integrated 457
CIL-EXPOSOME automatic profiling method, 671 potential 458
biomarkers (505 hydroxyl and 166 carboxylic acid biomarkers) 459
were found, as partially illustrated in Figure 5a. For example, 460
peaks 10 and 11 in Figure 5a are representative of extracted ion 461
chromatograms at m/z 356.1345/358.1397 and m/z 462
465.2120/469.2265, indicating possible hydroxyl and carbox- 463
ylic biomarkers, respectively. The MS spectra of the light and 464
heavy labeled samples (Figure 5b,c) further confirmed the 465
precursor ions of the paired peaks from the extracted ion 466
chromatograms. The use of the selected paired peaks after 467
chemical labeling as the targeted precursor ions facilitated the 468
subsequent MS/MS analysis. The biomarker in Figure 5b (m/z 469
356.1345/358.1397) was identified as 4-ethylphenol, an 470
exposure that results from food ingestion. The carboxylic 471
acid in Figure 5c (m/z 465.2120/469.2265) identified as 472
trans,trans-muconic acid, which is a urinary metabolite of 473
benzene. In addition to these compounds, the identities of four 474
other suspected biomarkers (listed in Table S8) that are 475
commonly used in consumer products as plasticizers and 476
preservatives were confirmed. 477

We further used the current method to measure several 478
targeted biomarkers in 9 individual urine samples. After 479
derivatization, the signal intensities for targeted compounds 480
showed significant increases compared to the signal intensities 481
for their free forms. The detection limit in our method was 482
comparable to that obtained with LC-QQQ, which is 483
considered as the gold standard for quantitation (Figure 5d). 484
For example, the LOD values of BPA are 0.39 and 0.15 ng/mL 485
for CIL-EXPOSOME and LC-QQQ, respectively. Further- 486
more, isotope labeling creates a convenient internal standard 487
for the absolute quantification of all biomarkers, especially for 488
the urine samples which exhibit significant and sample- 489
dependent matrix effects. Because the internal standard 490
coelutes with the analyte, it compensates for either ionization 491
enhancement or suppression caused by the matrix. In 492
conclusion, our method not only showed robust reliability in 493
quantification but also encompassed a broader coverage of 494
biomarkers compared with previous methods. 495

496 Using this method, a high concentration of benzo(a)anthracene,
497 methylparaben, 3,5-DHPPA, and genistein were detected in a
498 pooled mixture of urine. As shown in Figure 5e, two abundant
499 compounds, namely, 3,5-DHPPA ($10\,186.69 \pm 262.04$ ng/
500 mL) and genistein ($1\,995.32 \pm 202.04$ ng/mL), were food
501 additives. Another 7 hydroxyl compounds were also well-
502 detected, including plasticizers BPA (49.21 ± 1.21 ng/mL),
503 BPS (32.20 ± 2.76 ng/mL), and benzo(a)anthracene ($157.11 \pm$
504 10.74 ng/mL); personal care products methylparaben (453.04
505 ± 41.89 ng/mL) and triclosan (379.65 ± 4.65 ng/mL);
506 pesticide 4-bromophenol (4.03 ± 0.48 ng/mL); and PAH
507 exposure biomarker naphthol (19.92 ± 3.76 ng/mL). The
508 ubiquity of these biomarkers indicates that people are exposed
509 to xenobiotics on a daily basis. Notably, most of these
510 xenobiotics are biologically active as either endocrine-
511 disrupting chemicals (e.g., BPA, BPS, and triclosan) or
512 carcinogens (e.g., 4-bromophenol and naphthol).^{37,38}

513 In conclusion, a high-coverage urinary exposure biomarker
514 profiling method based on a stable isotope derivatization
515 approach was established in this study and provided enhanced
516 sensitivity and selectivity compared to existing methods. CIL-
517 EXPOSOME has overcome several hurdles encountered in
518 traditional exposome profiling platforms such as low sensitivity,
519 complex sample preparation, high cost of isotope standards,
520 and low-throughput profiling. Specifically, $^{12}\text{C}/^{13}\text{C}_2$ -dansyl
521 chloride (DNS) and $^{12}\text{C}/^{13}\text{C}_2$ -*p*-dimethylaminophenacyl bro-
522 mide (DmAP) were applied to label hydroxyl/amines/carboxyl
523 biomarkers, respectively, which are common functional groups
524 in most urinary biomarkers. This labeling method, together
525 with a simplified cleanup step, is effective not only in
526 introducing an economical isotope tag for accurate biomarker
527 quantification but also in improving the signal by up to several
528 orders of magnitude in electrospray ionization. In addition, this
529 strategy facilitated untargeted biomarker identification by
530 selecting the paired peaks with a defined mass tolerance.
531 Furthermore, we established a urinary exposome database with
532 MS and MS/MS information for more than 800 compounds
533 compiled from previous studies in human biological fluids to
534 facilitate exposome characterization. Operation using this
535 database has been automated using computational tools.
536 Using the CIL-EXPOSOME platform, 671 exposure biomarker
537 candidates from one injection were profiled in a 2 mL urine
538 sample. In sum, CIL-EXPOSOME provides a sensitive, cost-
539 effective, high-coverage, and automated exposome platform for
540 the analysis of both known and unknown biomarkers. We
541 believe that this platform provides a novel way to circumvent
542 the bottlenecks of current exposome approaches and
543 contributes to the future of exposome characterization.

544 ■ ASSOCIATED CONTENT

545 ● Supporting Information

546 The Supporting Information is available free of charge on the
547 ACS Publications website at DOI: 10.1021/acs.est.9b00285.

548 Detailed experimental results in Tests S1–S3, Tables
549 S1–S8, and Figures S1–S3 (PDF)

550 ■ AUTHOR INFORMATION

551 Corresponding Author

552 *Phone: +65 6790 5331; e-mail: mlfang@ntu.edu.sg.

553 ORCID

554 Tao Huan: 0000-0001-6295-2435

555 Mingliang Fang: 0000-0002-2204-9783

556 Notes

557 The authors declare no competing financial interest.
558 The CIL-EXPOSOME database, software, and usage protocol
559 may be accessed at [https://drive.google.com/drive/folders/](https://drive.google.com/drive/folders/1i1UNhfwMh_ry97TH6-FKGE_m_A-i-oIeU?usp=sharing)
560 [1i1UNhfwMh_ry97TH6-FKGE_m_A-i-oIeU?usp=sharing](https://drive.google.com/drive/folders/1i1UNhfwMh_ry97TH6-FKGE_m_A-i-oIeU?usp=sharing).

561 ■ ACKNOWLEDGMENTS

562 This work is funded by Singapore Ministry of Education
563 Academic Research Fund Tier 1 (M4011732.030), Start Up
564 Grant of Nanyang Technological University (M4081915,
565 M060030008), and Singapore National Environment Agency
566 (M4061617). We greatly appreciate Dr. Li Liang's group from
567 University of Alberta, Canada for the synthesis and shipment
568 of the $^{13}\text{C}_2$ -dansyl chloride and $^{13}\text{C}_2$ -*p*-dimethylaminophenacyl
569 bromide standards. Dr. Dai Chao, Wang Mengjing, and Tan
570 Jeremy from Nanyang Technological University, Singapore
571 and Dr. Allison Phillips from Duke University (Durham, NC,
572 United States) are gratefully acknowledged for helping with the
573 program, revising English grammar, and database setup.

574 ■ REFERENCES

- 575 (1) Wild, C. P. *Complementing the genome with an "exposome": the*
576 *outstanding challenge of environmental exposure measurement in*
577 *molecular epidemiology*. In AACR: 2005.
- 578 (2) Rappaport, S. M. Biomarkers intersect with the exposome.
579 *Biomarkers* **2012**, *17* (6), 483–489.
- 580 (3) Patti, G. J.; Yanes, O.; Siuzdak, G. Innovation: Metabolomics:
581 the apogee of the omics trilogy. *Nat. Rev. Mol. Cell Biol.* **2012**, *13* (4),
582 263.
- 583 (4) Johnson, C. H.; Ivanisevic, J.; Siuzdak, G. Metabolomics: beyond
584 biomarkers and towards mechanisms. *Nat. Rev. Mol. Cell Biol.* **2016**,
585 *17* (7), 451.
- 586 (5) Dennis, K. K.; Marder, E.; Balshaw, D. M.; Cui, Y.; Lynes, M. A.;
587 Patti, G. J.; Rappaport, S. M.; Shaughnessy, D. T.; Vrijheid, M.; Barr,
588 D. B. Biomonitoring in the era of the exposome. *Environ. Health*
589 *Perspect.* **2017**, *125* (4), 502–510.
- 590 (6) Rappaport, S. M.; Barupal, D. K.; Wishart, D.; Vineis, P.;
591 Scalbert, A. The Blood Exposome and Its Role in Discovering Causes
592 of Disease. *Environ. Health Perspect.* **2014**, *122* (8), 769–774.
- 593 (7) Want, E. J.; Wilson, I. D.; Gika, H.; Theodoridis, G.; Plumb, R.
594 S.; Shockcor, J.; Holmes, E.; Nicholson, J. K. Global metabolic
595 profiling procedures for urine using UPLC–MS. *Nat. Protoc.* **2010**, *5*
596 (6), 1005.
- 597 (8) Athersuch, T. J.; Keun, H. C. Metabolic profiling in human
598 exposome studies. *Mutagenesis* **2015**, *30* (6), 755–762.
- 599 (9) Miller, G. W.; Jones, D. P. The nature of nurture: refining the
600 definition of the exposome. *Toxicol. Sci.* **2014**, *137* (1), 1–2.
- 601 (10) Rappaport, S. M.; Smith, M. T. Environment and disease risks.
602 *Science* **2010**, *330* (6003), 460–461.
- 603 (11) Wild, C. P. The exposome: from concept to utility. *International*
604 *journal of epidemiology* **2012**, *41* (1), 24–32.
- 605 (12) Griffiths, W. J.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D. P.;
606 Deigner, H. P. Targeted metabolomics for biomarker discovery.
607 *Angew. Chem., Int. Ed.* **2010**, *49* (32), 5426–5445.
- 608 (13) Warth, B.; Spangler, S.; Fang, M.; Johnson, C. H.; Forsberg, E.
609 M.; Granados, A.; Martin, R. L.; Domingo-Almenara, X.; Huan, T.;
610 Rinehart, D.; Montenegro-Burke, J. R.; Hilmers, B.; Aisporna, A.;
611 Hoang, L. T.; Uritboonthai, W.; Benton, H. P.; Richardson, S. D.;
612 Williams, A. J.; Siuzdak, G. Exposome-Scale Investigations Guided by
613 Global Metabolomics, Pathway Analysis, and Cognitive Computing.
614 *Anal. Chem.* **2017**, *89* (21), 11505–11513.
- 615 (14) Zhou, J.; Yin, Y. Strategies for large-scale targeted
616 metabolomics quantification by liquid chromatography-mass spec-
617 trometry. *Analyst* **2016**, *141* (23), 6362–6373.
- 618 (15) Thomas, C. E.; Sexton, W.; Benson, K.; Sutphen, R.; Koomen,
619 J. Urine collection and processing for protein biomarker discovery and

- 620 quantification. *Cancer Epidemiol., Biomarkers Prev.* **2010**, *19* (4), 953–
621 959.
- 622 (16) Xu, C.; Li, C. Y.-T.; Kong, A.-N. T. Induction of phase I, II and
623 III drug metabolism/transport by xenobiotics. *Arch. Pharmacol. Res.*
624 **2005**, *28* (3), 249.
- 625 (17) Zhao, S.; Luo, X.; Li, L. Chemical isotope labeling LC-MS for
626 high coverage and quantitative profiling of the hydroxyl submetabo-
627 lome in metabolomics. *Anal. Chem.* **2016**, *88* (21), 10617–10623.
- 628 (18) Guo, K.; Li, L. Differential 12C-/13C-isotope dansylation
629 labeling and fast liquid chromatography/mass spectrometry for
630 absolute and relative quantification of the metabolome. *Anal. Chem.*
631 **2009**, *81* (10), 3919–3932.
- 632 (19) Guo, K.; Li, L. High-performance isotope labeling for profiling
633 carboxylic acid-containing metabolites in biofluids by mass spectrom-
634 etry. *Anal. Chem.* **2010**, *82* (21), 8789–8793.
- 635 (20) Arrivault, S.; Guenther, M.; Fry, S. C.; Fuenfgeld, M. M.; Veyel,
636 D.; Mettler-Altmann, T.; Stitt, M.; Lunn, J. E. Synthesis and use of
637 stable-isotope-labeled internal standards for quantification of
638 phosphorylated metabolites by LC–MS/MS. *Anal. Chem.* **2015**, *87*
639 (13), 6896–6904.
- 640 (21) Mung, D.; Li, L. Development of chemical isotope labeling LC-
641 MS for milk metabolomics: comprehensive and quantitative profiling
642 of the amine/phenol submetabolome. *Anal. Chem.* **2017**, *89* (8),
643 4435–4443.
- 644 (22) Yuan, B.-F.; Zhu, Q.-F.; Guo, N.; Zheng, S.-J.; Wang, Y.-L.;
645 Wang, J.; Xu, J.; Liu, S.-J.; He, K.; Hu, T.; et al. Comprehensive
646 Profiling of Fecal Metabolome of Mice by Integrated Chemical
647 Isotope Labeling-Mass Spectrometry Analysis. *Anal. Chem.* **2018**, *90*
648 (5), 3512–3520.
- 649 (23) Jiang, R.; Jiao, Y.; Zhang, P.; Liu, Y.; Wang, X.; Huang, Y.;
650 Zhang, Z.; Xu, F. Twin Derivatization Strategy for High-Coverage
651 Quantification of Free Fatty Acids by Liquid Chromatography–
652 Tandem Mass Spectrometry. *Anal. Chem.* **2017**, *89* (22), 12223–
653 12230.
- 654 (24) Parkinson, A. O. Biotransformation of Xenobiotics. In *Casarett*
655 *& Doull's Essentials of Toxicology*; Klaassen, C. D., Watson, J. B., Eds.;
656 McGraw-Hill: New York, 2010.
- 657 (25) Neveu, V.; Moussy, A.; Rouaix, H.; Wedekind, R.; Pon, A.;
658 Knox, C.; Wishart, D. S.; Scalbert, A. Exposome-Explorer: a manually-
659 curated database on biomarkers of exposure to dietary and
660 environmental factors. *Nucleic Acids Res.* **2017**, *45* (D1), D979–D984.
- 661 (26) Seiler, N.; Deckardt, K. Determination of amines and amino
662 acids in sugar-containing samples by dansylation. *Journal of*
663 *chromatography* **1975**, *107* (1), 227–229.
- 664 (27) Minocha, R.; Long, S. Simultaneous separation and
665 quantitation of amino acids and polyamines of forest tree tissues
666 and cell cultures within a single high-performance liquid chromatog-
667 raphy run using dansyl derivatization. *Journal of Chromatography A*
668 **2004**, *1035* (1), 63–73.
- 669 (28) Toyo'oka, T. Fluorescent tagging of physiologically important
670 carboxylic acids, including fatty acids, for their detection in liquid
671 chromatography. *Anal. Chim. Acta* **2002**, *465* (1–2), 111–130.
- 672 (29) Chen, D.; Han, W.; Su, X.; Li, L.; Li, L. Overcoming Sample
673 Matrix Effect in Quantitative Blood Metabolomics Using Chemical
674 Isotope Labeling Liquid Chromatography Mass Spectrometry. *Anal.*
675 *Chem.* **2017**, *89* (17), 9424–9431.
- 676 (30) Huan, T.; Troyer, D. A.; Li, L. Metabolite analysis and
677 histology on the exact same tissue: comprehensive metabolomic
678 profiling and metabolic classification of prostate cancer. *Sci. Rep.*
679 **2016**, *6*, 32272.
- 680 (31) Luo, X.; Zhao, S.; Huan, T.; Sun, D.; Friis, R. M. N.; Schultz,
681 M. C.; Li, L. High-performance chemical isotope labeling liquid
682 chromatography–mass spectrometry for profiling the metabolomic
683 reprogramming elicited by ammonium limitation in yeast. *J. Proteome*
684 *Res.* **2016**, *15* (5), 1602–1612.
- 685 (32) Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.;
686 Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; et al.
687 HMDB: the human metabolome database. *Nucleic Acids Res.* **2007**,
688 *35*, D521–D526.
- (33) Woodruff, T. J.; Zota, A. R.; Schwartz, J. M. Environmental
689 chemicals in pregnant women in the United States: NHANES 2003–
690 2004. *Environ. Health Perspect.* **2011**, *119* (6), 878.
- (34) Li, L.; Li, R.; Zhou, J.; Zuniga, A.; Stanislaus, A. E.; Wu, Y.;
692 Huan, T.; Zheng, J.; Shi, Y.; Wishart, D. S.; Lin, G. MyCompoundID:
693 Using an Evidence-Based Metabolome Library for Metabolite
694 Identification. *Anal. Chem.* **2013**, *85* (6), 3401–3408.
- (35) Huan, T.; Tang, C.; Li, R.; Shi, Y.; Lin, G.; Li, L. 696
697 MyCompoundID MS/MS Search: Metabolite Identification Using a
698 Library of Predicted Fragment-Ion-Spectra of 383,830 Possible
699 Human Metabolites. *Anal. Chem.* **2015**, *87* (20), 10619–10626.
- (36) Allen, F.; Pon, A.; Wilson, M.; Greiner, R.; Wishart, D. CFM-
700 ID: a web server for annotation, spectrum prediction and metabolite
701 identification from tandem mass spectra. *Nucleic Acids Res.* **2014**, *42*
702 (W1), W94–W99.
- (37) vom Saal, F. S.; Nagel, S. C.; Coe, B. L.; Angle, B. M.; Taylor, J.
704 A. The estrogenic endocrine disrupting chemical bisphenol A (BPA)
705 and obesity. *Mol. Cell. Endocrinol.* **2012**, *354* (1), 74–84.
- (38) Hecht, S. S. Human urinary carcinogen metabolites: biomarkers
707 for investigating tobacco and cancer. *Carcinogenesis* **2002**, *23* (6),
708 907–922.